Patent EA-000578-B1 (EA)
Title: Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
Inventor: GETMAN DANIEL P
IPC: A61P31/18
Filed: 1996-03-07
Abstract: 1. Compound represented by the formula:   or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein R<1> represents alkyl of 1-5 carbon atoms, alkenyl of 2-5 carbon atoms, alkynyl of 2-5 carbon atoms, hydroxyalkyl of 1-3 carbon atoms, alkoxyalkyl of 1-3 alkyl and 1-3 alkoxy carbon atoms, cyanoalkyl of 1-3 alkyl carbon atoms, imidazolylmethyl, -C2CONH2, -CH2CH2CONH2, -CH2S(O)2NH2, -CH2SCH3, -CH2S(O)CH3, -CH2S(O)2CH3, -C(CH3)2SCH3, -C(CH3)2S(O)CH3 or -C(CH3)2S(O)2CH3 radicals; R<2> represents radicals of alkyl of 1-5 carbon atoms, aralkyl of 1-3 alkyl carbon atoms, alkylthioalkyl of 1-3 alkyl carbon atoms, arylthioalkyl of 1-3 alkyl carbon atoms or cycloalkylalkyl of 1-3 alkyl carbon atoms and 3-6 ring member carbon atoms; R<3> represents radicals of alkyl radical of 1-5 carbon atoms, cycloalkyl of 5-8 ring members or cycloalkylmethyl radical of 3-6 ring members; R<10> represents hyrogen, alkyl, hydroxyalkyl or alkoxyalkyl radicals, wherein alkyl and alkoxy are each 1-3 carbon atoms; R<11> represents hydrogen, alkyl of 1-5 carbon atoms, hydroxyalkyl of 1-4 carbon atoms, alkoxyalkyl of 1-4 alkyl carbon atoms, benzyl, imidazolylmethyl, -CH2CH2CONH2, -CH2CONH2, -CH2CH2SCH3 or -CH2SCH3 radicals or the sulfone or sulfoxide derivatives thereof; R<4> represents aryl provided R<11> is other than a hydrogen radical, or R<4> represents benzo fused 5 to 6 ring member heteroaryl or benzo fused 5 to 6 ring member heterocyclo radicals; or a radical of the formula   wherein A and B each independently represent O, S, SO or SO2; R<6> represents deuterium, alkyl of 1-5 carbon atoms, fluoro or chloro radicals; R<7> represents hydrogen, deuterium, methyl, fluoro or chloro radicals; or a radical of the formula   wherein Z represents O, S or NH; and R<9> represents a radical of formula   wherein Y represents O, S or NH; X represents a bond, O or NR<21>; R<20> represents hydrogen, alkyl of 1 to 5 carbon atoms, alkenyl of 2 to 5 carbon atoms, alkynyl of 2 to 5 carbon atoms, aralkyl of 1 to 5 alkyl carbon atoms, heteroaralkyl of 5 to 6 ring members and 1 to 5 alkyl lcarbon atoms, heterocycloaikyl of 5 to 6 ring members and 1 to 5 alkyl carbon atoms, aminoalkyl of 2 to 5 carbon atoms, N-mono-substituted or N,N-disubstituted aminoalkyl of 2 to 5 alkyl carbon atoms wherein said substituents are radicals of alkyl of 1 to 3 carbon atoms, aralkyl of 1 to 3 alkyl carbon atoms radicals, carboxyalkyl of 1 to 5 carbon atoms, alkoxycarbonylalkyl of 1 to 5 alkyl carbon atoms, cyanoalkyl of 1 to 5 carbon atoms or hydroxyalkyl of 2 to 5 carbon atoms; R<21> represents hydrogen radical or alkyl radical of 1 to 3 carbon atoms; or the radical of formula -NR<20>R<21> represents a 5 to 6 ring member heterocycle radical; and R<22> represents alkyl radical of 1 to 3 carbon atoms or R<20>R<21>N-alkyl radical of 1 to 3 alkyl carbon atoms; and R<12> and R<13> each independently represent hydrogen, alkyl, aralkyl, heteroaralkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, alkoxyalkyl, aryl or heteroaryl radicals, wherein alkyl is 1-5 carbon atoms, cycloalkyl is 3-6 ring member cycloalkyl optionally benzo fused, and heteroaryl is 5 to 6 ring member heteroaryl optionally benzo fused. 2. Compound of Claim 1, or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein R<1> represents alkyl of 1-4 carbon atoms, alkenyl of 2-3 carbon atoms, alkynyl of 3-4 carbon atoms, cyanomethyl, imidazolylmethyl, -CH2CONH2-,-CH2CH2CONH2, -CH2S(O)2NH2, -CH2SCH3, -CH2S(O)CH3, -CH2S(O)2CH3, -C(CH3)2SCH3, -C(CH3)2S(O)CH3 or -C(CH3)2S(O)2CH3 radicals; R<2> represents radicals of alkyl of 3-5 carbon atoms, arylmethyl, alkylthioalkyl of 1-3 alkyl carbon atoms, arylthiomethyl or cycloalkylmethyl of 5-6 ring member carbon atoms radicals; R<3> represents alkyl of 1-5 carbon atoms, cycloalkylmethyl of 3-6 ring members, cyclohexyl or cycloheptyl radicals; R<4> represents phenyl, 2-naphthyl, 4-methoxyphenyl, 4-hydroxyphenyl, 3,4-dimethoxyphenyl, 3-aminophenyl or 4-aminophenyl radicals provided R<11> is other than a hydrogen radical; or R<4> represents 2-amino-benzothiazol-5-yl, 2-amino-benzothiazol-6-yl, benzothiazol-5-yl, benzothiazol-6-yl, benzoxazol-5-yl, 2,3-dihydrobenzofuran-5-yl, benzofuran-5-yl, 1,3-benzodioxol-5-yl or 1,4-benzodioxan-6-yl radicals; or a radical of the formula   wherein A and B each represent 0; R<6> represents deuterium, methyl, ethyl, propyl, isopropyl or fluoro radicals; and R<7> represents hydrogen, deuterium, methyl or fluoro radicals; or a radical of the formula   wherein Z represents O, S or MH; and R<9> represents a radical of formula   wherein Y represents O, S or NH; X represents a bond, O or NR<21>; R<20> represents hydrogen, alkyl of 1 to 5 carbon atoms, phenylalkyl of 1 to 3 alkyl carbon atoms, heterocycloalkyl of 5 to 6 ring members and 1 to 3 alkyl carbon atoms, or N-mono-substituted or N,N-disubstituted aminoalkyl of 2 to 3 alkyl carbon atoms wherein said substituents are alkyl radicals of 1 to 3 carbon atoms; and R<21> represents hydrogen or methyl radicals; or the radical of formula -NR<20>R<21> represents pyrrolidinyl, piperidinyl, piperazinyl, 4-methylpiperazinyl, 4-benzylpiperazinyl, morpholinyl or thiamorpholinyl radicals; and R<22> represents alkyl radical of 1 to 3 carbon atoms; and R<12> and R<13> each independently represent hydrogen, alkyl of 1-5 carbon atoms, phenylalkyl of 1-3 alkyl carbon atoms, 5 to 6 ring member heteroaralkyl of 1-3 alkyl carbon atoms, cycloalkyl of 3-6 ring members, cycloalkylmethyl of 3-6 ring members, hydroxyalkyl of 1-3 carbon atoms, methoxyalkyl of 1-3 alkyl carbon atoms or phenyl radicals. 3. Compound of Claim 2, or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein R<1> represents isopropyl, secbutyl, tertbutyl, 3-propynyl, cyanomethyl, imidazolylmethyl, -CH2CONH2' -CH2SCH3, -CH2S(O)CH3, -CH2S(O)2CH3, -C(CH3)2SCH3, -C(CH3)2S(O)CH3 or -C(CH3)2S(O)2CH3 radicals; R<2> represents isobutyl, n-butyl, CH3SCH2CH2-, phenylthiomethyl, (2-naphthylthio)methyl, benzyl, 4-methoxyphenylmethyl, 4-hydroxyphenylmethyl, 4-fluorophenylmethyl or cyclohexylmethyl radicals; R<3> represents propyl, isoamyl, isobutyl, butyl, cyclohexyl, cycloheptyl, cyclopentylmethyl or cyclohexylmethyl radicals; R<10> represents hydrogen, methyl, ethyl, propyl, methoxymethyl, methoxyethyl, hydroxymethyl or hydroxyethyl radicals; R<11> represents hydrogen, methyl, ethyl, propyl, isopropyl, butyl, secbutyl, isobutyl, tertbutyl, hydroxymethyl, hydroxyethyl, methoxymethyl or methoxyethyl radicals; R<4> represents phenyl, 2-naphthyl, 4-methoxyphenyl or 4-hydroxyphenyl radicals provided R<11> is other than hydrogen radical; or R<4> represents benzocthiazole-5-yl, benzothiazol-6-yl, benzoxazol-5-yl, 2,3-dihydrobenzofuran-5-yl, benzofuran-5-yl, 1,3-benzodioxol-5-yl, 2-methyl-l,3-benzodioxol-5-yl, 2,2-dimethyl-1,3-benzodioxol-5-yl, 2,2-dideutero-l,3-benzodioxol-5-yl, 2,2-difluoro-l,3-benzodioxol-5-yl or 1,4-benzodioxan-6-yl radicals; or a radical of the formula   wherein Z represents O, S or NH; and R<9> represents a radical of formula   wherein Y represents O, S or NH; X represents a bond, O or NR<21>; R<20> represents hydrogen, methyl, ethyl, propyl, isopropyl, isobutyl, benzyl, 2-(1-pyrrolidinyl)ethyl, 2-(1-piperidinyl)ethyl, 2-(1-piperazinyl)ethyl, 2-(4-methylpiperazin-1-yl)ethyl, 2-(1-morpholinyl)ethyl, 2-(1-thiamorpholinyl)ethyl or 2-(N,N-dimethylamino)ethyl radicals; R<21> represents a hydrogen radical; and R<22> represents methyl radical; and R<12> and R<13> each independently represent hydrogen, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexylmethyl, benzyl, phenylethyl, 2-pyridylmethyl, 3-pyridylmechyl, 4-pyridylmethyl, 2- (2-pyridyl) ethyl, 2-(3-pyridyl) ethyl, 2-(4-pyridyl) ethyl, furylmethyl, 2-furylethyl, 2-hydroxyethyl, 2-methoxyethyl or phenyl radicals. 4. Compound of Claim 3 or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein n represents 1; R<1> represents secbutyl, tertbutyl, isopropyl, 3-propynyl, cyanomethyl, or -C(CH3)2S(O)2CH3 radicals; R<2> represents benzyl, 4-fluorophenylmethyl or cyclohexylmethyl radicals; R<10> and R<11> each independently represent hydrogen, methyl or ethyl radicals; R<4> represents phenyl, 4-methoxyphenyl or 4-hydroxyphenyl radicals provided R<11> is other than a hydrogen radical; or R<4> represents benzothiazol-5-yl, benzothiazol-6-yl, 2,3-dihydrobenzofuran-5-yl, benzofuran-5-yl, 1,3-benzodioxol-5-yl, 2-methyl-1,3-benzodioxol-5-yl, 2,2-dimethyl-1,3-benzodioxol-5-yl, 2,2-dideutero-l,3-benzodioxol-5-yl, 2,2-difluoro-l,3-benzodioxol-5-yl, 1,4-benzodioxan-6-yl, 2-(methoxycarbonylamino)benzothiazol-6-yl or 2-(methoxycarbonylamino)benzimidazol-5-yl radicals; R<12> represents hydrogen or methyl radicals; and R<13> represents hydrogen, methyl, ethyl, propyl, cyclopropyl, isopropyl, benzyl, 2-phenylethyl, 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, 2-(2-pyridyl) ethyl, 2-(3-pyridylethyl, 2-(4-pyridyl) ethyl, furylmethyl, 2-furylethyl or 2-methoxyethyl radicals. 5. Compound of Claim 1 wherein said pharmaceutically acceptable salt is hydrochloric acid salt, sulphuric acid salt, phosphoric acid salt, oxalic acid salt, maleic acid salt, succinic acid salt, citric acid salt or methanesulfonic acid salt. 6. Compound of Claim 5 wherein said phannaceutically acceptable salt is hydrochloric acid salt, oxalic acid salt, citric acid salt or methanesulfonic acid salt. 7. Compound of Claim 1 which is 2S-[[(N-methylamino)acetyl]amino]-N-[2R-hydroxy-3-[[(1,3-benzodioxol-5-ylsulfonyl] (2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-3,3-dimethyl-butanamide; 2S-[[(N-methylamino)acetyl]amino]-N-[2R-hydroxy-3-[(1,3-benzodioxol-5-yl) sulfonyl] (2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-3-methyl-butanamide; 2S-[[(N-methylamino)acetyl]amino]-N-[2R-hydroxy-3-[[(1,3-benzodioxol-5-yl) sulfonyl] (2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-3-cyanopropanamide; 2S-[[(N-methylamino)acetyl]amino]-N-[2R-hydroxy-3-[[(1,3-benzodioxol